Osteoarthritis Global Market Report 2024

The global osteoarthritis market has grown rapidly in recent years. It will grow from $6.24 billion in 2023 to $6.87 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to aging population, obesity epidemic, advances in imaging, pain management.

The global osteoarthritis market is expected to see strong growth in the next few years. It will grow to $9.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to non-pharmacological approaches, disease-modifying osteoarthritis drugs (dmoads), personalized medicine, telehealth and remote monitoring. Major trends in the forecast period include regenerative therapies, wearable devices, artificial intelligence in diagnosis, digital health tools.

The growth of the osteoarthritis market is anticipated to be significantly influenced by the rising prevalence of obesity-related disorders. Obesity-related disorders encompass a spectrum of health issues that can emerge due to excess body fat. This condition typically results from an imbalance between caloric intake and expenditure, often associated with the consumption of highly processed foods and excessive alcohol consumption. Obesity can contribute to the development of osteoarthritis by exerting increased stress on joints, inciting inflammation, and causing hormonal changes that elevate the burden on the joints. For example, according to the World Obesity Atlas 2022, published by the World Obesity Federation, it is projected that by 2030, 1 billion individuals worldwide, comprising 1 in 7 men and 1 in 5 women, will grapple with obesity. Furthermore, the report suggests that this trend will continue to escalate, with an estimated 4 billion people, equivalent to 51% of the global population, being classified as either overweight or obese by 2035. Thus, the surge in obesity-related disorders is a key driver behind the expansion of the osteoarthritis market.

The increasing utilization of pain relievers is poised to be a significant catalyst for the growth of the osteoarthritis market. Pain relievers encompass medications or substances designed to alleviate pain by diminishing the perception of discomfort. They play a pivotal role in mitigating pain associated with various conditions or injuries. The widespread application of pain relievers in the management of osteoarthritis, driven by the imperative need for effective pain management, holds considerable potential to impact the osteoarthritis market. This trend can lead to heightened demand, exert an influence on treatment protocols, stimulate research and development initiatives, and elevate awareness surrounding the condition. As an illustrative instance, in June 2022, the Consumer Healthcare Products Association reported that about 80% of respondents expressed that their utilization of over-the-counter pain relievers has either remained consistent (49%) or increased (30%) over the past two years. Consequently, the prevalent use of pain relievers is propelling the growth of the osteoarthritis market.

The osteoarthritis market's expansion during the forecast period faces a significant impediment in the form of high treatment costs. The elevated cost associated with osteoarthritis treatment can pose formidable barriers to access and treatment adherence, particularly affecting individuals with limited insurance coverage or those who lack insurance altogether. This circumstance often leads to delayed diagnosis and treatment, thereby exacerbating the progression of the disease and heightening the risk of complications. As an example, in 2021, the National Library of Medicine, a reputable biomedical library, reported an estimated annual cost range for osteoarthritis management per individual, spanning from $700 to $15,600. Consequently, the elevated cost of treatments represents a hindrance to the growth of the osteoarthritis market.

Major companies engaged in the osteoarthritis market are directing their efforts toward the development of novel products and advanced treatment modalities, including small molecule inhibitors, intra-articular hyaluronic acid injections, and single-injection viscosupplements, to fortify their foothold in the market. For instance, in August 2021, Seikagaku Corporation, a pharmaceutical and medical device company headquartered in Japan, introduced HyLink, a single-injection viscosupplement intended for intra-articular administration to address knee osteoarthritis. The core component of this product is a crosslinked hyaluronate hydrogel created using Seikagaku's proprietary crosslinking technique. HyLink is anticipated to offer enduring relief from symptoms with a minimal 3ml dosage, as the highly viscoelastic hyaluronate hydrogel remains within the knee joint cavity for an extended period, enhancing lubrication and reducing pain.

In July 2022, Bioventus Inc., a medical device company based in the United States, completed the acquisition of CartiHeal Ltd. for a sum of $450 million. This strategic acquisition is expected to enhance Bioventus' joint preservation technology. It bolsters Bioventus' standing as a leader in the joint preservation technology sector, aligning with Bioventus' objectives related to sports medicine and comprehensive joint reconstruction. CartiHeal Ltd., headquartered in Israel, specializes in the development of medical devices designed for the treatment of cartilage and osteochondral defects in both arthritic and non-arthritic knee joints. This acquisition is set to augment Bioventus' capabilities and offerings in this domain.

Major players in the osteoarthritis market are Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Abbvie Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories Incorporation, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Zimmer Biomet Holdings Inc., Eisai Co. Ltd., Horizon Therapeutics PLC, Apotex Inc., Mallinckrodt Pharmaceuticals, Pacira BioSciences Inc., Bioventus Inc., Endo Pharmaceuticals Inc., Assertio Therapeutics Inc., Anika Therapeutics Inc., Abiogen Pharma Spa, Kolon TissueGene Inc., Ampio Pharmaceuticals Inc.

North America was the largest region in the osteoarthritis market in 2023. The regions covered in osteoarthritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the osteoarthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The primary treatments for osteoarthritis involve medication, surgical interventions, and therapy. Medication involves the use of drugs or pharmaceuticals to treat or alleviate the condition. Osteoarthritis pain can be managed with medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids. Diagnosis typically includes imaging studies and joint fluid analysis. Medications can be administered via different routes, including parenteral, topical, and oral, and are employed for treating various types of osteoarthritis, such as knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, and hand osteoarthritis. These treatments are primarily administered by healthcare professionals in hospitals and medical institutes.

This report provides osteoarthritis market statistics, including osteoarthritis industry global market size, regional shares, competitors with an osteoarthritis market share, detailed osteoarthritis market segments, market trends and opportunities and any further data you may need to thrive in the osteoarthritis industry. This osteoarthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoarthritis market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, weight management, exercise and physical activity, patient education, self-management programs and joint protection techniques. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoarthritis market also includes sales of viscosupplementation agents, analgesics, corticosteroids and assistive devices such as braces, canes, or shoe inserts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.